ARTICLE | Company News
Chroma, Macrophage deal
January 20, 2017 7:58 PM UTC
Chroma granted Macrophage worldwide rights to Chroma's Esterase Sensitive Motif (ESM) technology plus therapeutic assets in discovery, including a phosphoinositide 3-kinase (PI3K) inhibitor. ESM deliv...
BCIQ Company Profiles